...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive Diseases and Sciences >A Comparative Study on Endoscopic Ulcer Healing of Omeprazole Versus Rabeprazole with Respect to CYP2C19 Genotypic Differences
【24h】

A Comparative Study on Endoscopic Ulcer Healing of Omeprazole Versus Rabeprazole with Respect to CYP2C19 Genotypic Differences

机译：奥美拉唑与雷贝拉唑的内镜溃疡愈合对CYP2C19基因型差异的比较研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Omeprazole is mainly metabolized in the liver by CYP2C19, a genetically determined enzyme, while rabeprazole is mainly nonenzymatically degraded with a minor involvement by CYP2C19. We investigated the gastric ulcer healing effect of omeprazole versus rabeprazole evaluated endoscopically with reference to the different CYP2C19 genotypes. Eighty patients with active gastric ulcer were treated with a daily dose of 20 mg of omeprazole or 10 mg of rabeprazole. The endoscopic evaluation was performed at the baseline and 2- and 8-week posttreatment periods. The endoscopic improvement of gastric ulcer size and ulcer healing rates using a thin rubber disc with a diameter of 6 mm, were evaluated in relation to the CYP2C19 genotypic status. The mean 2-week posttreatment ulcer size value by rabeprazole did not significantly differ among the different CYP2C19 genotypes, whereas the mean value in the homozygous extensive metabolizer patients treated with omeprazole was significantly (P = 0.0057) greater than in those with rabeprazole. However, after the 8-week treatment, omeprazole and rabeprazole showed the similarly high healing rates of 87.8% (31/37) and 88.9% (32/36), respectively. Although both omeprazole and rabeprazole showed a high healing rate of gastric ulcer after the 8-week treatment period, the healing effect of rabeprazole appears to be relatively independent of the CYP2C19 status, resulting in an earlier repair of gastric mucosal damage evaluated endoscopically compared to that of omeprazole.
机译：奥美拉唑主要在肝脏中被CYP2C19（一种遗传确定的酶）代谢，而雷贝拉唑主要在非酶促降解下被CYP2C19少量参与。我们参考不同的CYP2C19基因型，在内镜下观察了奥美拉唑与雷贝拉唑的胃溃疡愈合效果。 80名活动性胃溃疡患者每天接受20毫克的奥美拉唑或10毫克的雷贝拉唑治疗。内镜评估是在基线以及治疗后2周和8周进行的。使用CYP2C19基因型状态评估了使用直径为6 mm的薄橡胶圆盘的内镜改善胃溃疡大小和溃疡愈合率的方法。在不同的CYP2C19基因型之间，雷贝拉唑治疗后2周的平均溃疡大小值无显着差异，而用奥美拉唑治疗的纯合子广泛代谢患者中的平均值显着（P = 0.0057）比雷贝拉唑治疗的患者大。然而，经过8周的治疗，奥美拉唑和雷贝拉唑的治愈率分别为87.8％（31/37）和88.9％（32/36）。尽管奥美拉唑和雷贝拉唑均在8周的治疗后均显示出较高的胃溃疡治愈率，但雷贝拉唑的治愈作用似乎相对独立于CYP2C19的状态，因此与之相比，经内镜评估胃黏膜损伤的修复更早奥美拉唑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号